Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B‐cell Lymphoma Patients: a Matched‐control Analysis From the Thai Lymphoma Study Group (tlsg)
Year: 2023
Type: article
Study design: Observational Study
Abstract: Treatments of patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) represent an unmet clinical need. Polatuzumab vedotin (Pola), an anti-CD79b antibody-drug-conjugate (ADC), combined with bendamustine-rituximab (BR), has recently been approved for these patients. However, there were limited data on real-life studies in R/R DLBCL, especially in Thailand. R/R DLBCL patients who received Pola-based regimens as a salvage treatment between 1 April 2021 and 30 March 2022 from the nationwide multi-center in Thailand were included in determining efficacy and safety in the real-world setting. Age, sex, and prior treatments-matched controls were selected from the database of the Thai lymphoma registry. The Pola group and historical control R/R DLBCL patients were compared. Thirty-five patients who received Pola-based treatment (Pola-BR 54.3% and Pola-R 45.7%) were included. The median age was 66 years (IQR 58–79), and the median number of prior treatments was 2 (range 1–4). The overall response rate (ORR) was 62.8%, with complete remission and partial remission of 17.1% and 45.7%. With a median follow-up of 11.8 months, the median progression-free survival (PFS) and overall survival (OS) were 10.6 months and 12.8 months, respectively. Grade 3–4 adverse events (AEs) were mainly hematological: anemia (8.6%), thrombocytopenia (5.7%), neutropenia (22.5%), and febrile neutropenia (8.6%). Compared with 180 matched patients who received non-pola-based therapy, there was a significantly higher ORR in Pola-based salvage treatments (62.8% vs. 33.3%, hazard ratio [HR] 3.52, 95% confidence interval [CI] 1.39-8.95, p < 0.01). The survival outcomes were also significantly superior in the Pola group: the median PFS 10.6 versus 4.2 months (HR 0.49; 95% CI, 0.29-0.85; p = 0.015), median OS 12.8 versus 7.5 months (HR 0.53; 95% CI, 0.34-0.84; p = 0.017). The use of Polatuzumab vedotin combination as a salvage treatment in R/R DLBCL demonstrated promising results with tolerable toxicities in the real-world setting. Keywords: aggressive B-cell non-Hodgkin lymphoma, chemotherapy, immunotherapy No conflicts of interests pertinent to the abstract.
Source: Hematological Oncology
DOI: 10.1002/hon.3165_570
Authors: T. Rattanathammethee, L. Norasetthada, U. Bunworasate, K. Wudhikarn, J. Julamanee, P. Noiperm, T. Lanamtieng, P. Phiphitaporn, M. Navinpipat, P. Kanya, D. Jit‐ueakul, S. Wongkhantee, T. Suwannathen, J. Chaloemwong, P. Wong, N. Makruasi, A. Khuhapinant, K. Prayongratana, P. Niparuck, N. Kanitsap, T. Suwanban, T. Intragumtornchai
Institutions: Chiang Mai University, Chulalongkorn University, Prince of Songkla University, Khon Kaen University, Chulabhorn Hospital, ChiangRai Prachanukroh Hospital, Navamindradhiraj University, Vajira Hospital, Khon Kaen Hospital, Nakornping Hospital, Naresuan University, Srinakharinwirot University, Siriraj Hospital, Mahidol University, Phramongkutklao Hospital, Phramongkutklao College of Medicine, Ramathibodi Hospital, Thammasat University, Rajavithi Hospital
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4379980482